Natco Pharma Ltd share price logo

Natco Pharma Ltd

NSE: NATCOPHARM

BSE: 524816

Small Cap

Pharma Sector

816.65

-2.50

(-0.31%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

What are INDmoney investors doing with Natco Pharma shares?

Based on platform-user behaviour - not analyst opinion or company fundamentals.

Search interest on INDmoney

+30%

Searches for Natco Pharma on INDmoney have increased by 30% over the last 30 days.

Investment activity on INDmoney

+104.93%

Investment activity in Natco Pharma among INDmoney users has increased by 104.93% over the last 30 days.

Among the most traded stocks

440th

Natco Pharma was the 440th most traded stock on INDmoney over the last 7 days.

Average holding period of indmoney investors

75 days

INDmoney investors hold Natco Pharma shares for an average of 75 days.

Key Events for Natco Pharma

Last Dividend Declared

1.50 per share, declared on 14/08/2026

View Dividend History

Natco Pharma Stock Performance

as on September 16, 2026 at 5:44 pm IST

  • Day's Low

    Day's High

    ₹801.00
    ₹828.75
    downward going graph

    1.92%

    Downside

    1.48%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    ₹789.00
    ₹1,226.80
    downward going graph

    3.39%

    Downside

    50.22%

    Upside

    downward going graph

Natco Pharma share price movements today

Previous Close
₹819.15
Open
₹816.55
Volume
3.04L
Upper Circuit
₹982.95
Lower Circuit
₹655.35
Day's Low - High
₹801.00 - ₹828.75
52 Week Low - High
₹789.00 - ₹1,226.80

Natco Pharma Historical Returns

1 Month Return
-7.94 %
3 Month Return
-3.8 %
1 Year Return
-3.87 %
3 Year Return
-5.67 %
5 Year Return
-15.3 %

Natco Pharma Fundamentals

as on September 16, 2026 at 12:14 pm IST

Market Cap

₹14,671.79 Cr

Return on Equity (ROE)

28.63

PE Ratio (TTM)

12.76

Return on capital employed (ROCE)

32.75

Industry PE ratio

51.81

Beta (LTM)

1.06

P/B Ratio

0

Dividend Yield

0

PEG Ratio

-0.41

Quarterly Earnings Growth YOY

-74.56

EPS (TTM)

76.64

Book Value

515.15

Natco Pharma Stock Valuation

as on September 16, 2026 at 12:14 pm IST

Natco Pharma in the last 5 years

  • Overview

  • Trends

Lowest (7.09x)

April 9, 2025

Today (12.76x)

September 11, 2026

Industry (51.81x)

September 11, 2026

Highest (90.32x)

April 6, 2022

LowHigh

Today’s Price to Earnings Ratio: 12.76x

Natco Pharma Technical Analysis

Track how Natco Pharma technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Moving Averages

Bearish

Neutral

Bullish

Bearish

Oscillators

Bearish

Neutral

Bullish

Bullish

Overall

Bearish9
Bullish3
Neutral3

Oscillators

Name

Value

Action

MACD level (12,26)
-0.21
Bullish
CCI (20)
-181.21
Bullish
RSI (14)
45.5
Neutral
Momentum (10)
-0.55
Bearish
ADI (14)
20.04
Neutral
Ultimate Oscillator (7,14,28)
55.82
Neutral

Moving Averages

Name

Value

Action

SMA (20)
816.29
Bearish
EMA (20)
816.32
Bearish
VWMA (20)
816.27
Bearish
SMA (50)
816.79
Bearish
EMA (50)
817.2
Bearish
SMA (200)
815.44
Bullish
EMA (200)
817.57
Bearish
KAMA (200)
816.94
Bearish
DEMA (200)
818.02
Bearish

Natco Pharma Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Natco Pharma with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
HOLD14,671.79-3.06%0.541,3714,078
BUY7,210.69-12.22%0.004132,013
BUY95,512.7323.99%0.603,50233,653
BUY1,09,625.6718.94%0.695,02651,180
BUY55,515.634.88%0.001,4146,445

Market expectation of Natco Pharma Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

HOLD

37.50%

Buy

25.00%

Hold

37.50%

Sell

Natco Pharma Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sales
1,031.4
758.6
1,068.3
1,362.6
1,371.1
474.8
1,221
1,328.9
1,363
647.3
739.1
735.2
Other Income
29.4
37
42
48.1
63.8
176.3
66.3
61.7
100
58.1
77.8
59.2
Total Income
1,060.8
795.6
1,110.3
1,410.7
1,434.9
651.1
1,287.3
1,390.6
1,463
705.4
816.9
794.4
Expenses
573.4
490.5
571
557.8
566.8
436
672.9
757.9
783.8
488.6
611.5
548.7
Operating Profit
458
268.1
497.3
804.8
804.3
38.8
548.1
571
579.2
158.7
127.6
186.5
Operating Profit Margin %
44.41%
35.34%
46.55%
59.06%
58.66%
8.17%
44.89%
42.97%
42.49%
24.52%
17.26%
25.37%
Profit Before Interest, Tax and Depreciation
487.4
305.1
539.3
852.9
868.1
215.1
614.4
632.7
679.2
216.8
205.4
245.7
Interest
4.2
4.6
6.2
5.2
4.1
4.4
10.2
3.2
13.1
9.5
10.9
13
Depreciation
43.6
44.2
55.5
44.1
45.8
47
98.3
57.6
52.4
46.2
50.4
47.1
Profit Before Tax
439.6
256.3
477.6
803.6
818.2
163.7
505.9
571.9
613.7
161.1
144.1
185.6
Tax Paid
70.6
43.6
91.3
135.1
141.7
31.3
99.9
91.6
95.8
20.7
-89.2
63.4
Profit After Tax
369
212.7
386.3
668.5
676.5
132.4
406
480.3
517.9
140.4
233.3
122.2
Total Net profit including share of profit / Loss from associate company
369
212.7
386.3
668.5
676.5
132.4
406
480.3
517.9
151.3
269
206.5
EPS
20.6
11.88
21.56
37.32
37.81
7.43
22.7
26.84
28.94
8.46
14.96
11.53
Actual EPS
20.6
11.88
21.56
37.32
37.81
7.43
22.7
26.84
28.94
8.46
14.96
11.53
Adjusted EPS
20.6
11.88
21.56
37.32
37.81
7.43
22.7
26.84
28.94
8.46
14.96
11.53
Diluted EPS
20.6
11.88
21.56
37.32
37.81
7.43
22.7
26.84
28.94
8.46
14.96
11.53

Natco Pharma Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Sales
2,184.8
2,094.5
1,915
2,052.1
1,944.8
2,707.1
3,998.8
4,429.5
4,078.3
Other Income
40.4
130.2
107.4
103.6
99
104.6
128.1
354.5
297.6
Total Income
2,225.2
2,224.7
2,022.4
2,155.7
2,043.8
2,811.7
4,126.9
4,784
4,375.9
Expenses
1,256.4
1,299.7
1,332.4
1,445.9
1,681.3
1,771.5
2,247.4
2,233.5
2,641.8
Operating Profit
928.4
794.8
582.6
606.2
263.5
935.6
1,751.4
2,196
1,436.5
Operating Profit Margin %
42.49%
37.95%
30.42%
29.54%
13.55%
34.56%
43.8%
49.58%
35.22%
Profit Before Interest, Tax and Depreciation
968.8
925
690
709.8
362.5
1,040.2
1,879.5
2,550.5
1,734.1
Interest
15.4
19.3
21.5
13.3
17.7
14.5
19.2
23.9
36.7
Depreciation
66.2
81
99.8
116.9
142.6
163.8
186.8
235.2
206.6
Profit Before Tax
887.2
824.7
568.7
579.6
202.2
861.9
1,673.5
2,291.4
1,490.8
Tax Paid
192
182.3
110.6
137.2
32.2
146.6
285.2
408
118.9
Profit After Tax
695.2
642.4
458.1
442.4
170
715.3
1,388.3
1,883.4
1,371.9
Total Net profit including share of profit / Loss from associate company
695.2
642.4
458.1
442.4
170
715.3
1,388.3
1,883.4
1,418.5
EPS
39.26
34.98
25.33
24.2
9.32
39.18
77.34
105.26
79.2
Actual EPS
39.26
34.98
25.33
24.2
9.32
39.18
77.34
105.26
79.2
Adjusted EPS
39.26
34.98
25.33
24.2
9.32
39.18
77.34
105.26
79.2
Diluted EPS
39.13
34.87
25.26
24.16
9.32
39.18
77.34
105.26
79.2

Natco Pharma Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Cash from Operating Activities
112.2
345.8
463.6
668.8
417.3
298.8
46.5
849.1
1,211.6
1,696.8
1,768.3
Cash Flow from Investing Activities
-176.3
-298.8
-1,116.3
-611.3
-175
-107.1
4
-465.3
-1,026.2
-1,436.5
-1,986.9
Cash Flow from Financing Activities
154
-47.7
650.9
-50.9
-250.8
-185.7
34.8
-363
-246.9
-210.7
297.5
Net Cash Flow
89.9
-0.7
-1.8
6.6
-8.5
6
85.3
20.8
-61.5
49.6
78.9

Natco Pharma Stock Shareholding Pattern

Numbers in percentages

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Promoters
49.71%
49.71%
49.71%
49.62%
49.62%
49.56%
49.56%
49.48%
49.48%
49.42%
49.42%
DII
11.23%
9.7%
7.87%
6.75%
5.57%
5.65%
5.82%
5.87%
5.39%
5.46%
5.62%
FII
0%
16.14%
17.45%
17.51%
17.94%
17.49%
15.51%
14.09%
15.16%
17.37%
16.99%
Public
25.32%
24.45%
24.97%
26.12%
26.87%
27.29%
29.11%
30.56%
29.96%
27.75%
27.97%
Total Outstanding Shares
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
17,91,09,870
Total Shareholders
2,07,571
2,28,467
2,51,485
3,02,944
3,45,332
4,05,222
4,29,434
4,19,699
4,24,167
4,10,970
4,03,166

Mutual Funds Buying / Exiting Natco Pharma

Holdings as of 15 Sep 2026 · based on the latest SEBI-mandated portfolio disclosures

Mutual Funds Buying Natco Pharma

Sorted by largest increase in holding, month-over-month.

Fund Name

Value of Holding

Increase (MoM)

Holding %

Bandhan Multi Cap Fund Direct Growth

Bandhan Multi Cap Fund Direct Growth

₹20.42 Cr

₹4.66 Cr (+29.55%)

0.75%

Nippon India Nifty Smallcap 250 Index Fund Dir Gr

Nippon India Nifty Smallcap 250 Index Fund Dir Gr

₹11.69 Cr

₹0.16 Cr (+1.39%)

0.34%

Mutual Funds Exiting Natco Pharma

Sorted by largest decrease in holding, month-over-month.

Fund Name

Value of Holding

Decrease (MoM)

Holding %

Tata Value Fund Direct Plan Growth

Tata Value Fund Direct Plan Growth

₹57.17 Cr

₹11.46 Cr (-16.70%)

0.68%

Natco Pharma Corporate Actions

View detailed summary of the earnings and dividend history of Natco Pharma.

  • Natco Pharma Ltd Earnings Results

    Natco Pharma Ltd’s net profit fell -57.04% since last year same period to ₹206.50Cr in the Q1 2026-2027. On a quarterly growth basis, Natco Pharma Ltd has generated -22.92% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Natco Pharma Ltd Dividends August,2026

    In the quarter ending June 2026, Natco Pharma Ltd has declared dividend of ₹1.50 per share on 14 Aug 2026 - translating a dividend yield of 0.55%.

    Read More about Dividends

Indices Featuring Natco Pharma Stock

Check stock indices that include Natco Pharma.

Nifty Small 100

₹19,343.70

-78.75 (0.41%)

Nifty Smallcap 50

₹9,688.35

-25.35 (0.26%)

S&P BSE 400 MidSmallCap

₹12,384.52

-22.32 (0.18%)

BSE Healthcare

₹50,214.52

-264.29 (0.52%)

Nifty Smallcap 250

₹17,822.85

-69.95 (0.39%)

Nifty 500

₹22,530.95

+53.50 (0.24%)

S&P BSE 250 SmallCap

₹7,026.95

-25.67 (0.36%)

Nifty MidSmallcap 400

₹20,708.65

-42.05 (0.20%)

BSE 500

₹35,254.37

+84.75 (0.24%)

Insights on Natco Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 1.72% to 1.92% in Jun 2026 quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 27.75% to 27.97% in Jun 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 157.4% return, outperforming this stock by 163.0%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 49.42% of holdings in Jun 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 50.8% return, outperforming this stock by 54.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, NATCOPHARM stock has moved down by -13.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 267.9 Cr → 206.5 Cr (in ₹), with an average decrease of 22.9% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 816.9 Cr → 794.4 Cr (in ₹), with an average decrease of 2.8% per quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 17.37% to 16.99% in Jun 2026 quarter

About Natco Pharma Ltd

Natco Pharma Limited is an international, RD focused pharmaceutical company that specialises in the development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). Natco sells products in over 40 countries, and provides contract manufacturing services for other pharmaceutical companies. The company was originally founded in 1981, and has since enjoyed significant growth, launching a variety of products and earning a number of milestones such as a compulsory license from Bayer for its patent protected anticancer drug Nexavar in 2012, and various first-to-market generic drugs including HEPCINAT (generic Sofosbuvir) and Epclusa (a single tablet regimen for the treatment of genotypes 2 and 3 chronic hepatitis C virus HCV infection). In 2021, Natco had 8 launches in the domestic market and acquired Dash Pharmaceuticals LLC in the US. Natco has 8 international subsidiaries, including the Philippines, Australia, Brazil and the US, constantly achieving the first generic to market for a variety of drugs. Natco's ambition for growth looks set to continue in 2022, with a number of new launches planned.

Revenue: ₹735.20Cr as on June 2026 (Q1 FY27)
Net Profit: ₹122.20Cr as on June 2026 (Q1 FY27)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
OrganisationNatco Pharma Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
CEOG S Murthy
E-voting on sharesClick here to vote

FAQs

What is Natco Pharma share price today?

Natco Pharma share price today stands at ₹816.65 as on . Natco Pharma share today touched a day high of ₹828.75 and a low of ₹801.

What is the 52 week high and 52 week low range for Natco Pharma share?

Natco Pharma touched a 52 week high of ₹1226.8 and a 52 week low of ₹789. Natco Pharma share price today i.e. is trending at ₹816.65, which is -33.43% down from its 52 week high and 3.50% up from its 52 week low.

What is Natco Pharma's market capitalisation today?

Natco Pharma market capitalisation is ₹14,671.79 Cr as on .

How to buy Natco Pharma shares?

To buy Natco Pharma shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for NATCOPHARM or Natco Pharma Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Natco Pharma shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Natco Pharma trading volume today?

Natco Pharma trading volume is 3.04L as on . This means that 3.04L shares of Natco Pharma were bought and sold on the stock market during today's trading session.

What are INDmoney investors doing with Natco Pharma shares right now?

Based on aggregated, anonymised INDmoney platform data, search interest and investment activity in Natco Pharma have both increased over the past 30 days, and the average INDmoney investor holds the stock for 75 days. This reflects platform activity only and is not investment advice.